Moreover, in vivo experiments demonstrating that inhibitors of CHK1 can increase the anti-tumor activity of gemcitabine have already been conducted in colorectal [53] and pancreatic cancer xenografts [47]. The gene discussed is CHEK1; the disease is neoplasm.